Basal insulin glargine vs prandial insulin lispro in type 2 diabetes

The Lancet

Volumn 372, Issue 9636, 2008, Pages 370-371

  Arnolds, Sabine ^a   Rave, Klaus ^a  

^a Profil Institut fur Stoffwechselforschung GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; GLYCOSYLATED HEMOGLOBIN; INSULIN GLARGINE; INSULIN LISPRO; ORAL ANTIDIABETIC AGENT;

ADD ON THERAPY; BLOOD GLUCOSE MONITORING; DRUG EFFECT; HUMAN; HYPOGLYCEMIA; LETTER; METABOLIC ACTIVATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 48149090010     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61151-4     Document Type: Letter

References (4)

1. Bretzel R., Nuber U., Landgraf W., Owens D., Bradley C., and Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 371 (2008) 1073-1084
2. Sanofi-Aventis. Amaryl: summary of product characteristics (2007), Sanofi-Aventis, Guildford, UK
3. Heise T., Nosek L., Spitzer H., et al. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab 9 (2007) 746-753
4. Heinemann L., Linkeschova R., Rave K., Hompesch B., Sedlak M., and Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23 (2000) 644-649